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Introduction
Methylglyoxal (MG) is a reactive dicarbonyl compound formed as a
natural by-product of metabolism, including glucose and fatty acid
pathways, found both intra- and extracellularly in vivo. Enzyme
defence mechanisms, especially the glyoxalase I system, usually
detoxify MG before it can damage cellular systems; however, in dia-
betes mellitus, glyoxalase expression is inhibited and glucose flux is
increased, leading to raised MG concentrations [1]. MG is associated
with oxidative stress, production of reactive oxygen species (ROS)
and apoptosis in cellular systems [2]. It is also a potent precursor of
advanced glycation end-products (AGEs) and forms adducts on free
amine and thiol groups, preferentially attacking arginine, but also
lysine, and cysteine residues of proteins and deoxyguanosine 
moieties in DNA. In forming AGEs, MG can alter the structure and
function of its target molecules and also provide ligands for the
receptor for AGEs (RAGE), which drives tissue damage by perpetu-
ating a pro-inflammatory and pro-adhesive milieu [3]. Denaturing of
proteins and RAGE-mediated inflammation contribute greatly to the
vascular and renal complications of diabetes.
In addition, diabetes patients suffer lower resistance to many
infections, including lower respiratory tract, urinary tract, skin and
mucous membrane infections [4], from a variety of bacteria, yeasts
and viruses. The cause of this increased infection was thought to
be high glucose providing a more favourable culture condition for
pathogens. Alternatively, inherent abnormalities in immune func-
tion associated with autoimmune disease have been postulated
[5], but no conclusive links have been provided.
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Abstract
Increased methylglyoxal (MG) concentrations and formation of advanced glycation end-products (AGEs) are major pathways of gly-
caemic damage in diabetes, leading to vascular and neuronal complications. Diabetes patients also suffer increased susceptibility to
many common infections, the underlying causes of which remain elusive. We hypothesized that immune glycation damage may account
for this increased susceptibility. We previously showed that the reaction mixture (RM) for MG glycation of peptide blocks up regulation
of CD83 in myeloid cells and inhibits primary stimulation of T cells. Here, we continue to investigate immune glycation damage, assess-
ing surface and intracellular cytokine protein expression by flow cytometry, T-cell proliferation using a carboxyfluorescein succinimidyl
ester assay, and mRNA levels by RT-PCR. We show that the immunomodulatory component of this RM was MG itself, with MG alone
causing equivalent block of CD83 and loss of primary stimulation. Block of CD83 expression could be reversed by MG scavenger 
N-acetyl cysteine. Further, MG within RM inhibited stimulated production of interleukin (IL)-10 protein from myeloid cells plus interferon
(IFN)- and tumour necrosis factor (TNF)- from T cells. Loss of IL-10 and IFN- was confirmed by RT-PCR analysis of mRNA, while
TNF- message was raised. Loss of TNF- protein was also shown by ELISA of culture supernatants. In addition, MG reduced major
histocompatibility complex (MHC) class I expression on the surface of myeloid cells and increased their propensity to apoptose. We
conclude that MG is a potent suppressor of myeloid and T-cell immune function and may be a major player in diabetes-associated sus-
ceptibility to infection.
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Dendritic cells (DC) are professional antigen-presenting cells
(APCs) [6], unique in their potency in stimulating primary immune
responses with establishment of memory [7]. Immature DC in the
periphery classically capture bacterial and other pathogenic anti-
gen through their expression of pattern recognition receptors.
These DC also process and present antigens, via major histocom-
patibility complex (MHC) apparatus, to T cells in secondary lym-
phoid organs [8]. This process results in proliferation of T-helper
(Th) cells, which can have effector or suppressor actions, depend-
ing upon the stimulation received. Cytokines produced by DC
influence both T-cell differentiation and function. DC also drive
regulation of central and peripheral tolerance to self-antigen.
We have previously shown that a reaction mixture (RM) for
MG-glycated peptide blocks up regulation of the maturation
marker CD83 on DC and reduces their ability to stimulate T cells
in allogeneic culture [9]. We now show that these effects are
caused by MG itself and further characterize immunomodulation
by this glycation precursor.
Materials and methods
Preparation of AGE peptide
The RM was prepared as described previously [9]. Briefly, angiotensin I
peptide (2.4 mM) was incubated with MG (0.25 M) and 0.02 M sodium
phosphate buffer (SPB) in a glass vial (37C, 24 hrs) and stored at 4C.
Analysis of reaction mixtures
The RM was analysed on Micromass TofSpec 2E MALDI-TOF mass spec-
trometer, as previously described [9]. The RM contained starting peptide,
peptide–MG–hydroimidazolone adduct (54 mu) plus one by-product of
unknown identity, 45 mu below starting peptide. A low level of endotoxin
was periodically confirmed using LAL Endosafe™ kit (Wilmington,
Charles River, MA, USA).
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated from human
venous blood, following informed consent, as described previously [9].
Briefly, the blood was diluted with culture medium and spun over Ficoll
Paque gradient (Amersham Biosciences, Chalfont St. Giles, UK).
Mononuclear cells aspirated from the gradient interfaces were washed
twice in culture medium, counted (trypan blue exclusion) and suspended
at 3.5 million/ml of culture medium containing 10% foetal calf serum
(FCS), unless otherwise stated.
Culture of cells
Freshly isolated PBMC were cultured with SPB (2 l/ml), RM (2 l/ml) or
500 M MG. The samples were incubated (37C, 5% CO2, humidified) for
2.5, 4 or 24 hrs. For assessment of intracellular cytokine, the samples were
incubated in the absence or presence of monensin (3 M, last 4 hrs of a
24 hrs culture). Stimulated cultures also contained lipopolysaccharide
(LPS) (1 g/ml, Escherichia coli 026:B6; Sigma, Pool, UK) or phorbol ester
(phorbol 12-myristate 13-acetate [PMA] 10 ng/ml) plus ionomycin (2 M)
for the entire culture.
Antibodies
Antibodies (Abs) to CD14 (FITC, MP9), CD4 (PE, SK3), CD4 (FITC, SK3),
CD3 (APC, UCHT1), HLA-DR (PE, L243), HLA-DR (APC, G46–6), CD69
(PE, L78), CD8 (APC, SK1) and CD83 (PE, HB15e) (BD Biosciences, San
Jose, CA, USA); tumour necrosis factor (TNF)- (FITC, B-D9), interferon
(IFN)- (FITC, D9D10) and interleukin (IL)-10 (PE, JES3–9D7) (Serotec,
Oxford, UK); CD3 (ECD, UCHT 1), CD8 (PC5, B9.11), CD19 (ECD, J4.119),
CD14 (PC5, RM052) and HLA-DR (PC5, Immu-357) (Coulter
Immunotech, High Wycombe, UK); HLA-ABC (FITC, W6/32) (eBioscience,
San Diego, CA, USA) and IL-4 (PE, 3007) (R&D systems, Minneapolis,
MN, USA) were used. Isotype-matched controls were obtained from the
same manufacturers.
Flow cytometry
Surface Ab labelling was performed in FACs buffer as before [9]. For intra-
cellular staining, before fixing, the cells were resuspended in 50 l
Leucoperm A (Serotec) diluted in 100 l FACs buffer (15 min.), washed
and resuspended in 100 l Leucoperm B (Serotec) plus 5 l anti-cytokine
antibody (30 min.). Data were acquired using a BD FACS Calibur flow
cytometer (BD Biosciences) (75,000–100,000 live cell events) and
analysed using WinList 5.0 software (Verity, ME, USA). Single-colour sam-
ples stained with CD8 or CD3 were acquired in each experiment for objec-
tive compensation in WinList. Relative cell counts were obtained by simul-
taneous acquisition of Flow-count fluorospheres (Coulter Immunotech).
Super-enhanced Dmax normalized subtraction (SED) was performed using
WinList software, giving percentage positive events and staining intensity
ratios for the positive events compared with isotpype control staining.
Mean fluorescence of staining for test histograms was also separately
recorded. Populations were discriminated as follows: myeloid cells were
defined as (CD3 and CD19) and HLA-DR. Within myeloid cells, putative
DC were also CD14, monocyte-like cells CD14 and classic monocytes
CD14 (high). T cells were taken as CD3 PBMC and also CD8high (CD8
T cells) or CD8CD4 (CD4 T cells).
RT-PCR
PBMC were resuspended in lysis buffer and mRNA was extracted using a
MACS isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Reverse transcription was undertaken using cloned AMV first-strand cDNA
synthesis kit (Invitrogen Life Technologies, Paisley, UK). Primers were
designed to span exons using Roche LightCycler primer design software
(Roche Diagnostics Ltd., Lewes, East Sussex, UK). The primers used had the
following sequences (5	 to 3	): IFN- forward CAGATGTAGCGGATAATGG,
reverse GTATTGCTTTGCGTTGG (amplicon 273 bp); TNF- forward
TCGAACCCCGAGTGAC, reverse GGAGCACATGGGTGGA (amplicon 212 bp);
IL-10 forward CTCCGAGATGCCTTCA, reverse GTTCACATGCGCCTTG
(amplicon 201 bp) and UbcH5b forward AGTGTTCAGCAGGTCC, reverse
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TCCGAGCAATCTCAGG (amplicon 318 bp). Roche LightCycler FastStart
DNA Master SYBR Green I reagents and LightCycler instrument were used
(45 amplification cycles of 95C/10 sec., 60C/5 sec. and 72C/8 sec.).
ELISA
TNF- ELISA was performed with supernatants from PBMC cultures,
Endogen Human TNF- ELISA kit reagents (Pierce Biotechnology, Inc.,
Rockford, IL, USA) and Dynatech Laboratories MRX plate reader (Dynatech
Laboratories, Inc., Chantilly, VA, USA).
Bead separation of cells
PBMC were washed and resuspended in buffer as per manufacturer’s
instructions. Microbeads (Miltenyi Biotec) were added and the cells were
incubated at 4–6C for 15 min. The cells were washed and run on deple-
tion (LD) or positive selection (MS) columns.
CFSE (carboxyfluorescein diacetate succinimidyl
ester) staining of cells
Cells were washed twice in sterile PBS and resuspended at 2 
 107/ml had
equal volume of CFSE added to a final concentration of 5 M and were
incubated in the dark for 3 min. One volume of FCS was added to stop
reaction and the cells were washed twice and resuspended for counting
and further culture.
Apoptosis assay
Cultured cells were washed and resuspended in 100 l annexin V binding
buffer plus 5 l annexin V antibody (FITC; BD Bioscience, Oxford, UK) and 10 l
propidium iodide. The cells were acquired by flow cytometry within 3 hrs.
Statistical analysis
Individual subtractions of isotypes from test histograms were assessed
using Kolmogorov–Smirnov (K–S) statistics, with the calculation of critical
D values (Dcrit). Only a Dcrit resulting in P  0.05 was deemed significant;
otherwise, the test results were taken as zero. A comparison of treatments
was done using the paired t-test (SigmaStat software, SPSS, Inc., Chicago,
IL, USA). P-values and standard deviations are shown.
Results
Previously described immunomodulation 
can be attributed to MG
An RM for the physiologically relevant AGE MG-derived
hydroimidazolone was previously shown to block up regulation
of CD83 on peripheral blood DC and monocytes and to impair DC
stimulatory capacity [9]. Treatment of PBMC with MG alone
exerted a comparable effect to RM on the percentage of mono-
cytes/DC expressing CD83 (Fig. 1A) and the intensity of CD83
staining (data not shown). In addition, block of CD83 expression
by RM could be prevented by pre-treatment with the MG scav-
enger N-acetyl cysteine (NAC) (Fig. 1B). Loss of DC stimulatory
capacity was also seen after MG treatment of DC before addition
to allogeneic T-cell responders in culture (Fig. 2). Responder
cells treated with MG before being stimulated by allogeneic DC
showed similar proliferation (CFSE assay) as buffer-treated con-
trols (Fig. 2), suggesting that MG affects T-cell stimulation
through damage to DC.
MG modulates cytokine production 
by myeloid and T cells
Before discovering that MG was the modulatory component of our
RM, we had shown that RM could inhibit stimulated cytokine pro-
duction from both myeloid and T cells.
Myeloid cell cytokine production
PBMC cultured with buffer or RM for 4 hrs showed low sponta-
neous production of the Th2 cytokine IL-4, the Th1 cytokine IL-12
and the immunoregulatory protein IL-10 by each of the CD14
(putative DC), CD14 (monocyte-like cell) and CD14 (classic
monocyte) myeloid populations. In order to aid assessment of
changes with treatment, myeloid cells were stimulated to produce
cytokine by co-culture with LPS. After 4 hrs of stimulated culture,
the RM reduced the number of IL-10-producing CD14 and
CD14 cells compared with buffer (Fig. 3A), with no overall loss
of myeloid cell number (data not shown). No effect of RM treat-
ment on IL-4 and IL-12 production was detectable (data not
shown). To confirm this loss of IL-10 protein, CD14 cells, puri-
fied by magnetic bead selection, were cultured with buffer or RM
before mRNA was extracted for gene expression analysis by RT-
PCR. Around four times less message for IL-10 was found in RM-
treated cells compared with buffer controls, with little change seen
in the housekeeping gene UbcH5B (data not shown). After 24 hrs
of culture with buffer or RM, myeloid cells were producing little
spontaneous IL-4, IL-12 or IL-10 and equivalent amounts of stim-
ulated IL-10, suggesting that cells can ‘recover’ from the earlier
RM-induced deficit.
T-cell cytokine production
Although myeloid cells were producing IL-10 in 4 hrs of stimu-
lated culture, CD8 and CD4 T cells were not being induced to
do the same and the RM had no detectable effect on induction of
this cytokine (data not shown). T cells from LPS-stimulated PBMC
cultures did however stain positive for IL-10 binding on their sur-
face (data not shown), suggesting that loss of myeloid cell
cytokine could have a later ‘knock-on’ effect.
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To study T-cell production of pro-inflammatory cytokines,
PBMC were cultured for 2.5 or 24 hrs with and without a mixture
of ionomycin and phorbol ester (PMA); in conjunction, these mol-
ecules are good stimulators of IFN- and TNF-, making assess-
ment of change easier. In control 2.5 hrs cultures, spontaneous
production of cytokine was low, but with stimulation, both CD4
and CD8 cells producing IFN- and TNF- were detected as antic-
ipated. RM treatment caused both CD8 and CD4 cells to pro-
duce less stimulated IFN- and TNF- than controls (Fig. 3B). This
loss was reflected in the proportions of cells producing cytokine
(data not shown) and the intensity of anti-cytokine antibody stain-
ing (e.g. SED intensity ratio of IFN- staining: buffer 49.77, RM
1.48). Slight reduction in the numbers of CD8 cells was seen in
the stimulated RM group compared with buffer (Fig. 4A), but this
did not account for loss of CD8IFN- or CD8TNF- cells.
Supernatant from stimulated RM cultures contained less TNF-
than buffer cultures, confirming loss of intracellular protein pro-
duction (Fig. 4B).
RT-PCR measurement of gene expression confirmed loss of
IFN-, with mRNA levels in CD3 PBMC substantially reduced
after 2.5 hrs of RM culture compared with buffer (Fig. 5A).
Message for IL-10 in the same cells was also reduced, more so
than for IFN- (Fig. 5A). In contrast to reduced TNF- protein, the
amount of TNF- mRNA in RM cultures was raised in relation to
buffer (Fig. 5A). The presence and purity of expected PCR prod-
ucts were confirmed by gel chromatography, reduction in IFN-
and IL-10 products being obvious by eye (data not shown). Gene
expression for the housekeeping gene UbcH5b did not vary signif-
icantly between treatments.
After 24 hrs of culture, no significant differences were detected
between RM and buffer culture for stimulated production of IFN-
and TNF-, again suggesting cell ‘recovery’ from early insult. RT-
PCR also revealed no variation in IFN- or TNF- mRNA between
culture conditions, but the level of IL-10 mRNA from RM-exposed,
stimulated CD3 cells was approximately four times less than that
from buffer-treated cells (Fig. 5B).
MG treatment of PBMC caused a similar loss in the numbers of
stimulated IFN- (Fig. 6) and TNF- CD8/CD4 T cells as RM
treatment. MG action on T-cell cytokine production appears to be
a direct effect (not reliant on APC orchestration), as depletion of
HLA-DR, CD19 and CD14 cells from PBMC before culture did
not prevent MG-induced loss of stimulated IFN- and TNF- (Fig. 6).
Fig. 1 Block of CD83 expression driven by MG. (A) Mean percent expression of CD83 on CD14 (black bars), CD14 (white bars) and CD14 (grey
bars) myeloid cells from PBMC cultured for 2.5 hrs with sodium phosphate buffer (BUFFER), 500 M methylglyoxal (MG) or reaction mixture (RM).
Extension bars represent standard deviations of means from three experiments, and P-values are given for paired t-test comparisons between treat-
ments. (B) Paired data sets (from separate experiments to those in (A)) for percent expression of CD83 on CD14, CD14 and CD14 myeloid cells
from PBMC cultured for 2.5 hrs with sodium phosphate buffer (BUF), 500 M methylglyoxal (MG) or reaction mixture (RM), with () and without (–)
600 M N-acetyl cysteine (NAC). P-values from paired t-tests are shown for the effect of NAC.
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MG reduces expression of MHC class I 
on myeloid cells
Having shown the loss of DC stimulatory capacity after MG
exposure, we were interested to see whether molecules involved
in antigen presentation were reduced. We had observed no
change in MHC II levels in myeloid cells after culturing with the
RM (data not shown); thus, we tested expression of MHC I after
MG exposure:
PBMC were cultured for 4 hrs with buffer or MG and expression
of MHC I was measured on the CD14, CD14 and CD14 myeloid
subsets. Regardless of treatment, staining for MHC I was seen on
close to 100% of all myeloid cells (Fig. 7A). However, MG reduced the
intensity of antibody staining on CD14 and CD14 cells compared
with buffer, suggesting less MHC I protein per cell (Fig. 7B).
Fig. 2 MG inhibits proliferation in allogeneic culture. Figure shows example analysis histograms for division and activation of CD3CD8 (second col-
umn) and CD3CD8 (third column) responders (CD19/CD14/HLA-DR-depleted PBMC) after a 5-day culture with LDC stimulators (non-adherent
myeloid cells enriched for DC). Previous to culture, responders and LDC were treated or not treated for 2.5 hrs with sodium phosphate buffer (BUF) or
methylglyoxal (MG) and untreated responders were mixed with treated LDC and vice versa. First column shows forward and side scatter properties of
5-day cell cultures and columns 2 and 3 show the CFSE and CD69 expression of CD8 and CD8 responders, respectively. Final column shows CFSE
fluorescence of the total gated population of cells (triangular gate on light scatter plot).
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Fig. 3 MG within RM drives altered cytokine protein expression. (A) Mean relative numbers of IL-10high CD14 (black bars), CD14 (white bars) and
CD14 (grey bars) myeloid cells from PBMC cultured for 4 hrs with sodium phosphate buffer (BUFFER) or reaction mixture (RM) plus monensin with
(stim) and without (unstim) 1 g/ml of LPS. (B) Mean relative numbers of IFN- and TNF- CD8 (black bars) and CD4 (grey bars) T cells from
PBMC cultured for 2.5 hrs with buffer (BUF) or RM plus a mixture of monensin, PMA and ionomycin. Extension bars represent standard deviations of
means from three experiments, and P-values are given from paired t-test comparisons between treatments.
Fig. 4 Numbers of T cells and
concentration of TNF- in super-
natants after stimulated culture.
(A) Mean relative numbers of
CD8 (black bars) and CD4
(grey bars) T cells from PBMC
after 2.5 hrs of culture with
either sodium phosphate buffer
(BUFFER) or reaction mixture
(RM) plus a mixture of mon-
ensin, phorbol ester and iono-
mycin in three similar experi-
ments. Extension bars represent
standard deviations of means.
n/s  not significant. (B) Mean
concentration of TNF- from the
supernatant of PBMC cultured
for 2.5 hrs with (stim) or without
(unstim) phorbol ester and iono-
mycin plus either sodium phos-
phate buffer (BUFFER) or reac-
tion mixture (RM). Extension
bars represent standard devia-
tions of means from triplicate
wells in three similar experi-
ments, and P-value is from a
paired t-test comparison
between treatments.
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Fig. 5 MG within RM drives altered cytokine mRNA expression. (A) Amounts of mRNA for TNF-, IFN-, IL-10 and housekeeping gene UbcH5B from
CD3 (positively selected by magnetic bead separation) PBMC cultured for 2.5 hrs with PMA and ionomycin plus RM (grey bars) relative to buffer (black
bars, given as 1 in each case). Extension bars represent standard deviations of means from three experiments. (B) Mean relative amounts of mRNA
for IL-10, IFN- and TNF- as well as the housekeeping gene UbcH5B in CD3 cells from PBMC cultured for 24 hrs with either sodium phosphate buffer
(black bars) or reaction mixture (grey bars) plus a mixture of monensin, phorbol ester and ionomycin (last 4 hrs). Amount of mRNA in reaction 
mixture culture is shown relative to buffer culture (in each instance given as 1). Extension bars represent standard deviations of means from three
similar experiments.
Fig. 6 Loss of IFN- production can be attributed to MG. Figure shows example test histograms for analysis of IFN- protein within CD8 and CD4
T cells from PBMC or PBMC depleted of HLA-DR, CD19 and CD14 cells cultured for 2.5 hrs with buffer, methylglyoxal (MG) or RM.
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MG increases myeloid cell apoptosis
MG has been linked to cell death in other systems, largely
through added oxidative stress [2]. We assessed whether MG
was predisposing PBMC in our cultures to apoptosis or necrosis:
cells were incubated with buffer or MG for 2.5, 4 and 24 hrs
before staining with FITC-conjugated annexin V and the vital dye
propidium iodide (PI). At 2.5 and 4 hrs, the proportions of
necrotic (PI), early apoptotic (annexin V) and late apoptotic
(annexin V/PI) cells were equivalent between treatments (Fig. 8).
After 24 hrs of culture, MG increased the percentages of early
apoptotic cells compared with buffer, but had not affected necrosis
or late apoptosis (Fig. 8).
Discussion
MG is a potent precursor of glycation damage, which adds to tis-
sue dysfunction in disease states of high MG concentration, such
as diabetes mellitus. Here, we show that MG is also an effective
modifier of immune function, responsible for blocking surface and
cytokine protein expression and for reducing the stimulatory
capacity of DC, after only short culture. MG also increases the
propensity of cells to apoptose after longer culture periods. We
suggest that this glycating agent may not only play a role in the
increased rate of infection seen in diabetes patients but also has
the potential for much farther-reaching consequences.
We previously showed that an RM for MG glycation of peptide
could block up regulation of the DC surface protein CD83 and
reduced DC potency for T-cell stimulation in allogeneic culture [9].
This RM could be seen by mass spectrometry to contain both MG-
derived hydroimidazolone peptide and unreacted peptide, so we
assumed that all of the highly reactive MG had been exhausted.
However, MG binds initially reversibly to proteins, with flux in and
out of solution [10]. We thus reconsidered that it may be the resid-
ual MG in solution that is driving immune modulation by the RM.
We show here that culture of PBMC with MG indeed caused equiv-
alent block of CD83 expression and loss of DC stimulatory capacity
to RM and that CD83 expression could be recovered by pre-treat-
ment with the MG scavenger NAC, in both MG and RM cultures.
NAC is also a free radical scavenger by virtue of the same thiol
group that is used to react with MG. It is thus possible that NAC
confers some antioxidant benefit to cells, aside from removing
MG from the system. Also, adding the equivalent RM without MG
(buffered peptide under reaction conditions) has no effect on cellular
protein expression [9].
We present data showing that RM blocks stimulated produc-
tion of IL-10 from myeloid cells and of IFN- and TNF- from 
T cells. Cytokines produced by myeloid cells can influence those
in T cells that they stimulate [11, 12]. While myeloid cells in our
cultures were producing IL-10, T cells were not being induced to
do so. T cells in these cultures stained positive for IL-10 on their
surfaces, suggesting that they were binding IL-10 made by the
myeloid cells. This advocates that loss of IL-10 production by
myeloid cells after exposure to MG may have an effect on the signals
received by T cells and thus on their future cytokine production
and function. While T cells in short cultures had not produced
detectable IL-10 protein, mRNA for IL-10 was reduced after RM
Fig. 7 MG reduces intensity of MHC I staining. (A) Mean percent expres-
sion of MHC class I on CD14, CD14 and CD14 myeloid cells from
PBMC cultured for 4 hrs with buffer (black bars) or 500 M MG (grey
bars). Extension bars represent standard deviations of means from three
experiments. (B) Paired data sets for mean fluorescence of MHC I stain-
ing on CD14, CD14 and CD14 myeloid cells from the same three
experiments. P-values from paired t-test comparisons between treat-
ments are given.
Fig. 8 MG induction of apoptosis. Figure shows mean percentage of total
PBMC that stained as necrotic (propidium iodide), early apoptotic
(annexin V) and late apoptotic (propidium iodide and annexin V)
after 2.5, 4 or 24 hrs of culture with sodium phosphate buffer or 500 M
MG. Extension bars represent standard deviations of means from three
experiments, and P-value from paired t-test comparisons between treat-
ments is given.
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culture, compared with buffer. This also suggests that the ability
of T cells to produce IL-10 may be compromised by MG.
Both RM and MG alone reduced stimulated production of pro-
inflammatory cytokines from T cells, after only short culture. In
the case of IFN-, this loss of protein could be attributed to
reduced mRNA. Loss of TNF- intracellular protein was confirmed
within the supernatants by ELISA; however, the message for TNF-
was raised after RM exposure at this time. This discrepancy
between message and protein suggests that the action of MG may
be post-translational within the TNF- pathway or that MG is alter-
ing the kinetics of TNF pathway activation/transcription.
MG also reduced the level of MHC I antibody staining on
myeloid cells compared with buffer culture. Less amount of this
antigen-presenting molecule on the cell surface may suggest
internalization or shedding of protein, with consequences for 
efficient T-cell priming. The inhibition of NK cell effector function
is related to MHC I expression on target cells [13]; thus, loss of
MHC I after MG exposure could also induce cell killing.
MG has been linked to cell death in several cellular systems,
largely through induction of ROS [2]. We found that MG increased
the levels of early apoptosis only after 24 hrs of culture, with no
obvious effects on necrosis. As this increased cell death was not
obvious early, or to a large extent, it may suggest that death is trig-
gered as a result of other MG-induced cellular changes and that
the described loss of surface and intracellular proteins is inde-
pendent of apoptosis induction.
The levels of MG are raised in diabetes patients, two- to six-
fold compared with controls [14]. A recent estimate of MG in
diabetes patients’ blood was in the region of 0.2 M [15].
However, the majority of MG is likely to be bound to protein
[10] and the amount in free circulation would be much less
than the actual level in the vasculature. Also, MG concentration
will vary locally depending upon the supply of precursors,
activity of detoxification systems and location of the cell/tissue.
A concentration of 310 M MG was reported in hamster cell
cultures [16]. Thus, immune damage by 500 M MG shown
here may well be relevant in vivo, but more ‘physiological’ 
levels (50 M) still inhibited CD83 up-regulation in myeloid
cells (unpublished data).
We now start to understand how advanced glycation by MG
may have roles in immune regulation in diabetes as well as in vas-
cular dysfunction: We have seen that in DC, MG blocks expression
of CD83, an important protein in DC:T-cell contact and stimulation
[17]. We demonstrated a reduction in the capacity of these profes-
sional APCs to stimulate T cells in culture and disruption in pro-
duction of pro-inflammatory and immunoregulatory cytokines at
protein level, plus variable effects on gene expression. PBMC
exposed to MG do not mount suitable defences against pro-
inflammatory stimuli, which may include in vivo pathogens. This
lack of reaction is unlikely to be an induction of tolerance, as DC
were not up-regulating the inhibitory molecule immunoglobulin-
like transcript-3 (ILT-3) (unpublished data) and lost the ability to
produce IL-10. IL-10 plays a key role in limiting inflammatory
reactions, including direct effects on the function of both myeloid
and CD4 T cells [18].
This immune damage may have a role in diabetes, especially in
the susceptibility to infection, with pathogens being able to thrive
while immune defence is compromised. A number of studies have
reported immune dysfunction in diabetes, with reduced Th1-asso-
ciated chemokine receptors and cytokines [19], impaired T-cell
proliferation in a rat model [20] and commonly, reduced IFN-
production at the onset of disease [19, 21–23]. These changes are
often not seen in long-standing disease, an observation easily
explained by considering the self-promoting, escalating nature of
tissue RAGE ligation. In established disease, immune dysfunction
may be masked by a RAGE-associated pro-inflammatory and pro-
adhesive milieu [24].
Although MG-induced damage in our system was short term,
our model was a closed system, with contained populations of
cells and limited dose of MG. In vivo, we would expect cells to
encounter continually raised MG levels [14]. In this way, damage
may be sustained, resulting in chronic immune dysfunction. The
use of cellular cultures or animal models to assess damage by MG
is necessary prior to investigating equivalent damage in patients.
We used freshly isolated blood mononuclear cells, not matured or
differentiated unnaturally by cytokines and growth factors, mean-
ing that our results should, to a substantial extent, be applicable
to in vivo reactions. The use of a single bolus of MG and a cellular
in vitro system are limitations to this study. However, we are inter-
ested to further research by investigating the effect of repeated
small doses of MG, the nature of the TNF- protein/message
dichotomy and the result of cytokine loss on the differentiation of
T cells after stimulation by MG-exposed APC. It will also be impor-
tant to identify key targets of MG damage, in cells of the immune
system and elsewhere, in order to further knowledge of MG-asso-
ciated disease and to provide direction for therapeutic advances:
MG reacts with arginine, lysine and cysteine residues of proteins,
as well as with guanine units in DNA [25]. Depending upon the
configuration and environment of proteins, some residues will be
more prone to attack from MG than others, creating ‘hot spots’ for
glycation [26, 27]. Such damage is likely to affect the structure
and function of many physiological proteins and enzymes, not just
in an immunological setting. Bioinformatics analysis of receptor
binding domains has shown that arginine and lysine are the most
common amino acids at such sites of protein–protein interaction
[28], and MG has already been implicated in the inactivation of
cysteine active sites in cysteine proteases [29], which are involved
in multiple physiological processes, including antigen presenta-
tion. The list of potential MG targets and the capacity for damage
are thus huge, with disruption of protein binding and enzyme
functions likely in numerous bodily settings. It may be interesting
to perform proteomic analyses on immune cells exposed to MG to
identify molecules containing AGEs. These altered proteins would
provide clues to the key pathways of MG damage that lead to the
observed immunomodulation.
The levels of related -dicarbonyls glyoxal and 3-deoxyglu-
cosone plus glycolytic by-product glucosamine are also raised in
diabetes, accompanied by dysregulation of lipids and their
metabolites. Any of these metabolic imbalances could also impact
on immune function and are worthy of future investigation.
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In conclusion, we have shown that methylglyoxal potently mod-
ifies immune function, causing multiple and varied deficiencies and
reducing the ability of immune cells to respond appropriately to
stimuli. We suggest that these findings may indicate a role for MG
in the susceptibility of diabetes patients to infection, on top of the
well-documented vascular dysfunction through AGE formation.
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